BGI Genomics Co., Ltd.
华大基因
300676
Shenzhen Stock Exchange
Company Profile
The company places high importance on innovation and technology R&D, maintaining substantial investment in upstream molecular testing technologies, information technology, and application fields such as reproductive health, tumor prevention and control, and infectious disease management. Over the years, this commitment has resulted in a series of significant patent achievements. As of June 30, 2025, the company and its wholly-owned and controlled subsidiaries held a total of 769 authorized patents, including 660 invention patents, 80 utility model patents, and 29 design patents. Additionally, the company owns 1,069 registered trademarks and has obtained 898 software copyrights for its independently developed software in areas such as bioinformatics analysis. The company is focused on industrializing two core products. One is the ChatGeneT platform, which leverages the independently developed GeneT multi-modal large model for genetic testing and the "Qingjian" expert knowledge base. By deeply exploring the layered relationships among genetic variations, clinical phenotypes, and clinical evidence, it forms an intelligent solution for genetic counseling scenarios. Equipped with capabilities such as precise multi-modal information integration, AI-powered analysis, and automated generation of consultation-enhancing dialogues, the platform has already established in-depth collaborations and joint R&D initiatives with several top-tier tertiary hospitals in China. These efforts aim to extend evidence-based genetic interpretation capabilities from high-level medical institutions to primary care settings, significantly improving outpatient consultation efficiency and medical service quality at all levels of hospitals, and supporting the high-quality, efficient development of the national tiered healthcare system. The company possesses strong expertise and extensive experience in constructing biological laboratories, including high-throughput sequencing labs and molecular laboratories. It is one of the world's largest medical genetic testing centers, operating 23 genetic testing laboratories across eight countries with a total area of approximately 40,000 square meters. These laboratories have cumulatively operated safely for over 4.22 million hours. As of June 30, 2025, the company has collaborated with thousands of medical institutions globally, establishing over 1,000 joint laboratories covering more than 100 countries and regions. The application of genetic sequencing technology in clinical settings—exemplified by non-invasive prenatal genetic testing, HPV genotyping, tumor genetic testing, and genetic disease testing—has gained widespread recognition. The company boasts comprehensive qualifications and advantages. As of June 30, 2025, 19 of its units hold Medical Institution Practice Licenses, and 17 medical testing laboratories have passed technical acceptance as clinical gene amplification testing laboratories. Key testing items, including single-gene genetic disease mutation detection, non-invasive prenatal testing for fetal chromosomal aneuploidy, low-depth whole-genome sequencing (CNV-seq), human papillomavirus (HPV) genotyping, and familial breast cancer gene mutation testing, have completed clinical gene amplification testing technology filings. Additionally, three medical testing laboratories are among the first pilot units approved for the clinical application of high-throughput gene sequencing technology in genetic disease diagnosis, preimplantation genetic diagnosis, and tumor diagnosis and treatment. The company has obtained 253 medical device registration certificates and filing certificates from the National Medical Products Administration (NMPA), along with 387 international medical device qualifications covering over 20 countries and regions, including the EU, Japan, Australia, Thailand, Saudi Arabia, Colombia, and Brazil, ensuring continuous compliance with market requirements in multiple jurisdictions. Furthermore, the company’s non-invasive prenatal genetic testing products have obtained 60 qualifications in regions such as the EU, Malaysia, Thailand, Saudi Arabia, the UK, India, Australia, Colombia, and the EAEU (Eurasian Economic Union), while its colorectal cancer testing products have received 63 qualifications in Brazil, Thailand, Saudi Arabia, Colombia, the UK, Australia, and other countries, facilitating global product promotion.
Full description
As a global leader in the genomics industry, BGI is driven by its mission to "make gene technology benefit humanity." With over two decades of talent cultivation, scientific research, and industrial development, the company has established a marketing and service network spanning over 100 countries and all provinces, autonomous regions, and municipalities in China. It has become one of the few technology companies covering the entire industry chain and all application fields in the genomics sector. Leveraging its advanced, comprehensive, and large-scale multi-omics platforms, BGI has emerged as one of the world's leading scientific technology service providers and precision medical service operators. The company's core business involves providing research services, comprehensive precision medical testing solutions, and health management services to scientific research institutions, enterprises, public organizations, medical institutions, and public health organizations through multi-omics and big data technologies such as genetic testing, mass spectrometry, bioinformatics analysis, and medical AI large models. Guided by its commitment to advancing life science research, promoting the application of life big data, and improving global healthcare standards, BGI strives to accelerate technological innovation and safeguard the global community's health and well-being, building on its achievements in genomics research and the application of precision testing technologies in public health.In the field of reproductive health, BGI offers a complete "five pre-" maternal and infant health management product system, covering premarital, preconception, prenatal, neonatal, and childhood stages. For tumor prevention and control, it has developed a full-life-cycle closed-loop management system encompassing "prevention, screening, diagnosis, and monitoring" of tumors, providing comprehensive testing services at every stage. In chronic disease management, BGI is dedicated to improving the efficiency of screening and treatment for cardiovascular, cerebrovascular, and cognitive disorders, advocating for a treatment model focused on prevention and proactive health. In infection prevention and control, the company has built precise testing product solutions ranging from common community infections to complex hospital-acquired infections, meeting testing needs across all scenarios. BGI is headquartered in Shenzhen, China, with branches and medical laboratories in major domestic cities such as Beijing, Tianjin, Wuhan, Shanghai, Harbin, and Shijiazhuang. It also operates overseas centers and core laboratories in regions including Hong Kong (China), Europe, and Latin America, forming a network that "covers China and radiates globally." Its business reaches over 100 countries and regions worldwide, serving more than 2,000 research institutions and over 2,400 medical institutions in China—including more than 600 tertiary hospitals—as well as collaborating with over 3,000 overseas medical and scientific research institutions across Europe, the Americas, and Asia-Pacific. BGI has established partnerships with health authorities in more than 30 countries and regions.